Could Baroreceptor Activation Therapy Be the Future for Treating Hypertension and Other Chronic Cardiovascular Conditions?
Version of Record online: 19 JAN 2010
© 2010 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 12, Issue 4, pages 288–291, April 2010
How to Cite
Ram, C. V. S. (2010), Could Baroreceptor Activation Therapy Be the Future for Treating Hypertension and Other Chronic Cardiovascular Conditions?. The Journal of Clinical Hypertension, 12: 288–291. doi: 10.1111/j.1751-7176.2009.00252.x
- Issue online: 5 APR 2010
- Version of Record online: 19 JAN 2010
- Manuscript received November 4, 2009; accepted November 14, 2009
- 5Treatment of hypertension with an implantable electronic device. JAMA. 1965;191:113–117., .
- 10Prolonged activation of the baroreflex abolishes reduced kidney mass, salt-induced hypertension. Hypertension. 2007;50:e85., , , et al.
- 11Baroreflex activation therapy normalizes gene expression of components of the beta-adrenergic receptor signaling pathway in LV myocardium of dogs with chronic heart failure. Eur Heart J. 2007;28 (Abstract Supplement):818–819., , , et al.
- 13Sustained blood pressure reduction by baroreflex hypertension therapy with a chronically implanted system: 3-year data from the Rheos DEBuT study in patients with resistant hypertension. J Hypertens. 2009;27(suppl). In press., , , et al.
- 14Long term baroreflex hypertension therapy significantly lowers ambulatory blood pressures in patients with resistant hypertension. J Clin Hypertens. 2008;10:271., , , et al.
- 16Baroreflex activation therapy preserves eGFR in hypertensive patients with stage 2 and 3 chronic kidney disease: results from european and United States trials of the Rheos® system. J Am Soc Nephrol. 2009;20., , , et al.